Knight Therapeutics Inc T.GUD

COVID-19: Ceapro (CZO) and Knight (GUD)

[stockfy]

All eyes are on PFE, BNTX, MRNA, JNJ and AZN regarding the COVID-19 vaccines, so profitable and debt-free Ceapro (CZO) is an unknown healthcare company that has a collaboration with the McMaster University and currently develops inhalable therapeutic for COVID-19, as shown below:

https://www.globenewswire.com/news-release/2020/11/27/2135353/0/en/Ceapro-Inc-Reports-2020-Third-Quarter-and-Nine-Month-Financial-Results-and-Operational-Highlights.html


Initial clinical trial results are already very promising and more results will be out in the next weeks.

However, cash-rich CZO is not dependent on the COVID-19 medicine, because it already sells other products to the health care and cosmetic industries (i.e. beta glucan, avenanthramides), so it expects double-digit revenue growth this year, according to the CEO's latest statements.

As a result, CZO generates positive operating cash flow and free cash flow.

On top of this, debt-free CZO has a strong presence in China where it experiences very strong demand for its beta glucan.

Hopefully, GUD will make a deal with CZO and gets exposure to its promising products, technology and research.

 

[EbbFlow88]

Funny enough, these are my two largest holdings. Both companies have rock solid balance sheets with promising futures and leaders who are on their own path and sometimes to a fault, care less about the market and mainly about their respective growth plans. I'm not sure I see these two partnering up, but I strongly believe that both will be great investments for the patient investor.

[stockfy]

Agree. CZO will be acquired by a larger healthcare company thanks to its inhalable therapeutic for COVID-19 and its PGX oat beta glucan that will be used for the cholesterol reducing pill and a functional drink, facts below:   https://www.ceapro.com/nutraceuticals/oat-beta-glucan